title: Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications.
abstract: Using the data of 723 chronic myeloid leukemia (CML) patients in the chronic phase, we analyzed the prognostic value of the Sokal, Euro, and EUTOS scores as well as the level of BCR-ABL1 and the achievement of complete cytogenetic response (CCgR) at 3 months of imatinib therapy in relation to the so-called current survival measures: the current cumulative incidence (CCI) reflecting the probability of being alive and in CCgR after starting imatinib therapy; the current leukemia-free survival (CLFS) reflecting the probability of being alive and in CCgR after achieving the first CCgR; and the overall survival. The greatest difference between the CCI curves at 5 years after initiating imatinib therapy was observed for the BCR-ABL1 transcripts at 3 months. The 5-year CCI was 94.3% in patients with BCR-ABL1 transcripts ≤ 10% and 57.1% in patients with BCR-ABL1 transcripts > 10% (P = 0.005). Therefore, the examination of BCR-ABL1 transcripts at 3 months may help in early identification of patients who are likely to perform poorly with imatinib. On the other hand, CLFS was not significantly affected by the considered stratifications. In conclusion, our results indicate that once the CCgR is achieved, the prognosis is good irrespective of the starting prognostic risks.
authors.affiliation: Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.
authors.forename: Tomas
authors.initials: T
authors.lastname: Pavlik
authors.forename: Eva
authors.initials: E
authors.lastname: Janousova
authors.forename: Jiri
authors.initials: J
authors.lastname: Mayer
authors.forename: Karel
authors.initials: K
authors.lastname: Indrak
authors.forename: Marie
authors.initials: M
authors.lastname: Jarosova
authors.forename: Hana
authors.initials: H
authors.lastname: Klamova
authors.forename: Daniela
authors.initials: D
authors.lastname: Zackova
authors.forename: Jaroslava
authors.initials: J
authors.lastname: Voglova
authors.forename: Edgar
authors.initials: E
authors.lastname: Faber
authors.forename: Michal
authors.initials: M
authors.lastname: Karas
authors.forename: Katerina
authors.initials: K
authors.lastname: Machova Polakova
authors.forename: Zdenek
authors.initials: Z
authors.lastname: Racil
authors.forename: Eva
authors.initials: E
authors.lastname: Demeckova
authors.forename: Ludmila
authors.initials: L
authors.lastname: Demitrovicova
authors.forename: Elena
authors.initials: E
authors.lastname: Tothova
authors.forename: Juraj
authors.initials: J
authors.lastname: Chudej
authors.forename: Imrich
authors.initials: I
authors.lastname: Markuljak
authors.forename: Eduard
authors.initials: E
authors.lastname: Cmunt
authors.forename: Tomas
authors.initials: T
authors.lastname: Kozak
authors.forename: Jan
authors.initials: J
authors.lastname: Muzik
authors.forename: Ladislav
authors.initials: L
authors.lastname: Dusek
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate; D015466:Leukemia, Myeloid, Chronic-Phase / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D011743:Pyrimidines / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000235:genetics* / Q000378:metabolism; D012074:Remission Induction; D012107:Research Design; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; C581634:BCR-ABL1 fusion protein, human; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D012333:RNA, Messenger; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl